You are here: Industry Insights > Market News > NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

chinadailyAugust 21, 2019

Tag: NMPA , Announcement , Drug Standards

Favorites

To promote the consistency evaluation of the quality and efficacy of generic drugs, and clarify the relationship between the registration standards of generic drugs and the national drug standards such as the Pharmacopoeia of the People's Republic of China, on August 2, 2019, NMPA issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content,

please email: Julia.Zhang@ubmsinoexpo.com to delete.

Previous:Nabriva’s bacterial pneumonia drug gets US regulatory approval

Next:NMPA Issued the Notice on Expanding the Pilot of the Medical Device Registrant System

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Gan & Lee Pharmaceuticals is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial.

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs | Pharmasources.com

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Related News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

You may like
More>>

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Related News

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

You may likeMore>>

You may like
More>>